FinanceRecent
Lilly to acquire Merida Biosciences for up to $2.875 billion
Investing.com✓
Original Reporting
AI EXECUTIVE SUMMARY
Eli Lilly announced it will acquire Merida Biosciences, a privately held biotech firm, in a deal valued at up to $2.875 billion. The transaction combines Lilly’s large‑scale drug development platform with Merida’s pipeline of antibody‑drug conjugates. Completion is expected later this year, subject to regulatory approval.
WHY IT MATTERS
The acquisition could broaden Lilly’s oncology portfolio and affect its market valuation.
Eli Lilly announced it will acquire Merida Biosciences, a privately held biotech firm, in a deal valued at up to $2.875 billion. The transaction combines Lilly’s large‑scale drug development platform with Merida’s pipeline of antibody‑drug conjugates. Completion is expected later this year, subject to regulatory approval.
This story was originally reported by Investing.com. As an automated real-time news aggregator, NewsToolBar provides multi-perspective indexing and AI summarization while directing full readership directly to primary publisher sources.
ALSO REPORTED BY OTHER SOURCES (2)
Global Market: Japan stocks see sector rotation as tech shares tumble
Child trust fund firms face review over efforts to find who owns £1.5bn worth of pots
Community Sentiment & Coverage Reliability
Crowd-sourced evaluation based on verified reader feedback
Rate Coverage Tone:
No reader evaluations recorded yet — be the first to rate the coverage tone above!
Quick Story Reactions:
Community Discussion (0)
Join the Community Discussion
Sign in or create a free reader account to post comments, upvote analysis, and share your perspective.